Latest News

Happy with previous assignments delivered by Aagami, its Netherlands HQ'd client has given Aagami a broader and long term assignment, for partnering in Asia region.

The client has a game changing First-in-class phase-3-ready drug candidate for Post-Operative Fibrosis (POF) with incredible adhesion prevention results.

The asset has an untapped $2.5 billion market potential. The drug prevents adhesion formation & delivers clinically relevant outcomes, key to surgeon adoption, reimbursement & commands premium pricing. Client recently released clinical trial results show that it is the first drug to show a statistically significant PREVENTION of adhesions following surgery.

Aagami is excited with this new assignment and is looking forward to enabling partnerships for the client in Asia.

Aagami team are happy to anounced that their Louisiana based Biotechnology client have given another assignment (3rd from them)  to support their cross border partnering. This time the mandate is for global and not restricted to any geography. In previous assignment, Aagami got a US$ 10 Million deal for the same client.

The client company specializes in innovative cancer treatment and their mission is to improve the overall patient condition through innovative bioimmunotherapy with proven treatment protocols, to lower deaths associated with cancer and reduce the cost of cancer treatment.

With a dedicated team in India, Aagami looks forward to put its best foot forward in bringing yet another success to its client who has known and appreciated Aagami work for a long time now.

This time, Aagami has a new client from South Korea. The recent trips to the country has been fruitful. Apart from this new assignment, more are in discussion. 

The assignment received is for outlicensing client's Anti-Retinal-Disease and Anti-cancer Drugs. 

Client has a novel and leading-edge HTS anti-HIV drug screening technique and Novel CPP technique and molecules. The mandate received is for North America region.

Updates at Aagami for May 2017:

  • New Client Win: Outreach and Business Development for a high growth US Med Tech company which has a promise to impact billions
  • New Client Win - Partnering support to a US based bio-targeted nanomedicines company with world-wide exclusive rights to a novel and innovative drug-targeting platform technology
  • Aagami to attend BIO International Convention, 40+ meetings already scheduled with pre-defined agenda.

Another day, Another assignment for Aaagami. Client is a high growth US MedTech, advancing the next generation of affordable, portable, minimally invasive surgical tools and technologies, which can be used everywhere, everyday, by everyone. Thus, has the promise to impact billions.

Aagami is excited to be a part of this inspiring and humanitarian opportunity. Aagami has deployed its specialised resources and connections, to draw water from the wells, for the client.

 

Aagami has received a new assignment from a new client for strategic advisory and partnership development.

Client is a bio-targeted nanomedicines company with world-wide exclusive rights to a novel and innovative drug-targeting platform technology developed at Cedars-Sinai Medical Center in Los Angeles.

The technology is based on generating self-assembling bio-targeted nanoparticles, called Eosomes. The structural basis of the Eosomes is a recombinant protein that has three functional domains:
1) receptor binding 2) endosomal penetration and 3) therapeutic capture

The Eosomes protein binds the therapeutic through noncovalent electrostatic interaction driving the self-assembly of the Eosomes.

Updates at Aagami for April 2017

  • New Client Win for Aagami. UK based Client is has unique nanotechnology based delivery system that works with multiple forms such as topical, oral and injectable
  • Aagami client JRF Global completes an action packed result focused trip to California. Both CEOs and also JRF BD Head North America were present
  • Aagami registers for BIO International Convention June 19-22, 2017, in San Diego
  • Aagami CEO to visit Japan, Korea, India in August 2017

Aagami announces a new client win. Aagami has received a mandate for strategic advisory and cross border licensing partnering.

The  UK based client's proprietary nanotechnology drug delivery platform is based on a specialist formulation of silicon that enhances drug bioavailability and therapeutic compliance through optimized solubility, stability and controlled therapeutic drug release. The particle contains hundreds of channels (mesopores) in a honeycomb porous structure to facilitate this. They are made from FDA GRAS approved materials. It is claimed to be the Best Drug Delivery Solution Available Today, that also  works with multiple forms such as topical, oral and injectable.

Aagami looks forward to bringing success to its new client.

Updates at Aagami:

  • New client win for Aagami - Netherlands HQ'd company with First-in-class phase-3-ready drug candidate for Post Operative Firbrosis (POF)
  • Aagami CEO attends a fruitful BIO Asia in Japan 14-15 March
  • Aagami CEO completes a successful business trip to Japan and Korea (March 10-29)
  • Aagami CEO to visit San Francisco, San Diego and Los Angeles, along with client CEO for high level strategic meetings for co-development partnerships (March 27 to April 7)

In keeping up with the annual tradition, Aagami is participating in JP Morgan Healthcare conference and BioTech Showcase this January 2017. Both events are like pilgrimage for the Lifesciences Industry professionals and brings about major global partnerships and advancements. Last year Aagami had a very busy and fruitful participation with over 45 one-to-one meetings.

Read more...

Aagami has been appointed for BD support, by an independent global Contract Research Organization (CRO) offering comprehensive non clinical GLP research services for regulatory submissions, worldwide.

Read more...

A UK based pharma company has appointed Aagami to look for strategic partnership relating to their branded generics laxative for treatment of chronic constipation and faecal impaction, for India market.

Read more...